TY - JOUR T1 - Genotyping <em>KRAS</em> and <em>EGFR</em> Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment JF - Cancer Genomics - Proteomics JO - Cancer Genomics Proteomics SP - 531 LP - 541 DO - 10.21873/cgp.20155 VL - 16 IS - 6 AU - HELENA LINARDOU AU - VASSILIKI KOTOULA AU - GEORGE KOUVATSEAS AU - GIANNIS MOUNTZIOS AU - VASILIOS KARAVASILIS AU - EPAMINONDAS SAMANTAS AU - ANNA KALOGERA-FOUNTZILA AU - DESPINA TELEVANTOU AU - KYRIAKI PAPADOPOULOU AU - XANTHIPI MAVROPOULOU AU - EMILY DASKALAKI AU - THOMAS ZARAMBOUKAS AU - IOANNIS EFSTRATIOU AU - SOFIA LAMPAKI AU - GRIGORIOS RALLIS AU - ELENI RES AU - KONSTANTINOS N. SYRIGOS AU - PARIS A. KOSMIDIS AU - DIMITRIOS PECTASIDES AU - GEORGE FOUNTZILAS Y1 - 2019/11/01 UR - http://cgp.iiarjournals.org/content/16/6/531.abstract N2 - Background/Aim: KRAS mutations are reported in 20-25% of non-small cell lung cancer (NSCLC) and their prognostic role is unclear. We studied KRAS and EGFR genotyping in Greek NSCLC patients. Patients and Methods: KRAS and EGFR genotypes were centrally evaluated in 421 NSCLC patients (diagnosed September 1998 -June 2013) and associated with clinicopathological parameters. Outcome comparisons were performed in 288 patients receiving first line treatment. Results: Most patients were male (78.6%), &gt;60 years old (63.9%), current smokers (51.1%), with adenocarcinoma histology (63.9%). EGFR and KRAS mutations were found in 10.7% and 16.6% of all histologies, respectively, and in 14.9% and 21.9% of adenocarcinomas. At 4.5 years median follow-up, KRAS status was an independent negative prognostic factor for overall survival (OS, p=0.016). KRAS mutations conferred 80% increased risk of death in patients receiving first-line treatment (p=0.002). Conclusion: The presence of KRAS mutations is an independent negative prognosticator among Greek NSCLC patients and an independent response predictor to first line treatment. ER -